Literature DB >> 10891628

Significant interaction between clozapine and cocaine in cocaine addicts.

C K Farren1, F A Hameedi, M A Rosen, S Woods, P Jatlow, T R Kosten.   

Abstract

Because clozapine may be prescribed to cocaine abusing patients with schizophrenia, we studied cocaine-clozapine interactions in a controlled setting. Eight male cocaine addicts underwent four oral challenges with ascending doses of clozapine (12.5, 25 and 50 mg) and placebo followed 2 h later by a 2-mg/kg dose of intranasal cocaine. Subjective and physiological responses, and serum cocaine levels were measured over a total 4-h period. Clozapine pretreatment increased cocaine levels during the study and significantly increased the peak serum cocaine levels in a dose dependent manner. In spite of this elevation in blood levels, clozapine pretreatment had a significant diminishing effect upon subjective responses to cocaine, including 'expected high', 'high' and 'rush', notably at the 50 mg dose. There was also a significant effect upon 'sleepiness', 'paranoia' and 'nervous'. Clozapine caused a significant near-syncopal episode in one subject in the study, requiring his removal from the study. Clozapine had no significant effect on baseline pulse rate and systolic blood pressure, but it attenuated the significant pressor effects of the single dose of intranasal cocaine. These data suggested a possible therapeutic role for clozapine in the treatment of cocaine addiction in humans, but also suggests caution due to the near-syncopal event and the increase in serum cocaine levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891628     DOI: 10.1016/s0376-8716(99)00114-3

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  11 in total

Review 1.  Substance abuse and schizophrenia: pharmacotherapeutic intervention.

Authors:  Alan I Green; Douglas L Noordsy; Mary F Brunette; Christopher O'Keefe
Journal:  J Subst Abuse Treat       Date:  2007-06-15

Review 2.  [Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review].

Authors:  T Wobrock; R D'Amelio; P Falkai
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

Review 3.  Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations.

Authors:  Douglas M Ziedonis; David Smelson; Richard N Rosenthal; Steven L Batki; Alan I Green; Renata J Henry; Ivan Montoya; Joseph Parks; Roger D Weiss
Journal:  J Psychiatr Pract       Date:  2005-09       Impact factor: 1.325

Review 4.  Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.

Authors:  Joseph T Coyle
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

5.  Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebo-controlled fMRI study.

Authors:  Birgit Abler; Susanne Erk; Henrik Walter
Journal:  Psychopharmacology (Berl)       Date:  2007-01-31       Impact factor: 4.530

Review 6.  Drug models of schizophrenia.

Authors:  Hannah Steeds; Robin L Carhart-Harris; James M Stone
Journal:  Ther Adv Psychopharmacol       Date:  2015-02

Review 7.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Douglas L Noordsy; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

Review 8.  Treatment of patients comorbid for addiction and other psychiatric disorders.

Authors:  Kathleen T Brady; Marcia L Verduin; Bryan K Tolliver
Journal:  Curr Psychiatry Rep       Date:  2007-10       Impact factor: 5.285

9.  Prevalence of psychotic symptoms in substance users: a comparison across substances.

Authors:  Matthew J Smith; Jagadisha Thirthalli; Arbi Ben Abdallah; Robin M Murray; Linda B Cottler
Journal:  Compr Psychiatry       Date:  2008-09-23       Impact factor: 3.735

Review 10.  Antipsychotic medications for cocaine dependence.

Authors:  Blanca I Indave; Silvia Minozzi; Pier Paolo Pani; Laura Amato
Journal:  Cochrane Database Syst Rev       Date:  2016-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.